{
  "posts": [
    {
      "thread": {
        "uuid": "188e4c70e7ecd6ba16e4800323464e5d47637362",
        "url": "http://omgili.com/ri/jHIAmI4hxg9BcPFu_4VOJxXOPE7_XaSqp9Z2h_C16MuFpAX6dnivoiu9WHJu7HYnCrI_yRTY7sC_5JVHn5vbePOg1aaXp71I_VDYNSSvg5EzsGgjZhsAs5RcsXgGFP2u",
        "site_full": "www.onenewspage.com",
        "site": "onenewspage.com",
        "site_section": "http://www.onenewspage.com/rss/latest/Markets.rss",
        "site_categories": [
          "news",
          "entertainment",
          "education"
        ],
        "section_title": "Latest Markets News on One News Page",
        "title": "Better Buy: Amgen Inc. vs. Johnson & Johnson",
        "title_full": "Better Buy: Amgen Inc. vs. Johnson & Johnson - One News Page",
        "published": "2016-11-08T18:20:42.698+02:00",
        "replies_count": 0,
        "participants_count": 1,
        "site_type": "news",
        "country": "US",
        "spam_score": 0.0,
        "main_image": "http://cdn.newsserve.net/ONPglobe128.png",
        "performance_score": 0,
        "domain_rank": 91686,
        "social": {
          "facebook": {
            "likes": 0,
            "comments": 0,
            "shares": 0
          },
          "gplus": {
            "shares": 0
          },
          "pinterest": {
            "shares": 0
          },
          "linkedin": {
            "shares": 0
          },
          "stumbledupon": {
            "shares": 0
          },
          "vk": {
            "shares": 0
          }
        }
      },
      "uuid": "188e4c70e7ecd6ba16e4800323464e5d47637362",
      "url": "http://omgili.com/ri/jHIAmI4hxg9BcPFu_4VOJxXOPE7_XaSqp9Z2h_C16MuFpAX6dnivoiu9WHJu7HYnCrI_yRTY7sC_5JVHn5vbePOg1aaXp71I_VDYNSSvg5EzsGgjZhsAs5RcsXgGFP2u",
      "ord_in_thread": 0,
      "author": "onenewspage.com",
      "published": "2016-11-08T18:20:42.698+02:00",
      "title": "Better Buy: Amgen Inc. vs. Johnson & Johnson",
      "text": "Amgen and Johnson & Johnson have been great choices for investors in the past. Which is the smarter pick now?",
      "highlightText": "",
      "highlightTitle": "",
      "language": "english",
      "external_links": [],
      "entities": {
        "persons": [],
        "organizations": [
          {
            "name": "johnson & johnson amgen",
            "sentiment": "positive"
          },
          {
            "name": "johnson & johnson",
            "sentiment": "positive"
          },
          {
            "name": "amgen inc.",
            "sentiment": "positive"
          }
        ],
        "locations": []
      },
      "crawled": "2016-11-08T18:20:42.698+02:00"
    },
    {
      "thread": {
        "uuid": "19c5e017a2ecd2c54655cc720255fdbe560054da",
        "url": "http://omgili.com/ri/jHIAmI4hxg_lXD5cNG56Yn7FsrOQ2Z2qbAG7YmvLHoIbRXgyVM8V0x5BCb5Ll3evfpHfqvMlc5qxbHQCLYTBWLJcDuLDKxQhRZk7qa8tTA.bVnncmOPpLQ--",
        "site_full": "www.fool.com",
        "site": "fool.com",
        "site_section": "http://www.fool.com/feeds/index.aspx?id=foolwatch&format=rss2",
        "site_categories": [
          "news"
        ],
        "section_title": "Motley Fool Headlines",
        "title": "Better Buy: Amgen Inc. vs. Johnson & Johnson",
        "title_full": "Better Buy: Amgen Inc. vs. Johnson & Johnson -- The Motley Fool",
        "published": "2016-11-08T02:00:00.000+02:00",
        "replies_count": 0,
        "participants_count": 1,
        "site_type": "news",
        "country": "US",
        "spam_score": 0.0,
        "main_image": "https://g.foolcdn.com/image/?url=http%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F418437%2Famgen-scientists.jpg&h=630&w=1200&op=resize",
        "performance_score": 0,
        "domain_rank": 1336,
        "social": {
          "facebook": {
            "likes": 1,
            "comments": 0,
            "shares": 1
          },
          "gplus": {
            "shares": 0
          },
          "pinterest": {
            "shares": 0
          },
          "linkedin": {
            "shares": 0
          },
          "stumbledupon": {
            "shares": 0
          },
          "vk": {
            "shares": 0
          }
        }
      },
      "uuid": "19c5e017a2ecd2c54655cc720255fdbe560054da",
      "url": "http://omgili.com/ri/jHIAmI4hxg_lXD5cNG56Yn7FsrOQ2Z2qbAG7YmvLHoIbRXgyVM8V0x5BCb5Ll3evfpHfqvMlc5qxbHQCLYTBWLJcDuLDKxQhRZk7qa8tTA.bVnncmOPpLQ--",
      "ord_in_thread": 0,
      "author": "foxnews.com",
      "published": "2016-11-08T02:00:00.000+02:00",
      "title": "Better Buy: Amgen Inc. vs. Johnson & Johnson",
      "text": "Amgen and Johnson & Johnson have been great choices for investors in the past. Which is the smarter pick now?",
      "highlightText": "",
      "highlightTitle": "",
      "language": "english",
      "external_links": [],
      "entities": {
        "persons": [],
        "organizations": [
          {
            "name": "johnson & johnson amgen",
            "sentiment": "positive"
          },
          {
            "name": "johnson & johnson",
            "sentiment": "positive"
          },
          {
            "name": "amgen inc.",
            "sentiment": "positive"
          }
        ],
        "locations": []
      },
      "crawled": "2016-11-08T19:44:17.471+02:00"
    },
    {
      "thread": {
        "uuid": "a5599ab62691f3bd336eb6e4abdeac345336cf42",
        "url": "http://omgili.com/ri/jHIAmI4hxg9BcPFu_4VOJxXOPE7_XaSqp9Z2h_C16MuFpAX6dnivotWIYqINysAU6KpzwR2avPjBlQcvvJGukn7GazLHxCNfYPkRqcwDXXg80bc52MwUuQ--",
        "site_full": "www.onenewspage.com",
        "site": "onenewspage.com",
        "site_section": "http://www.onenewspage.com/rss/latest/Markets.rss",
        "site_categories": [
          "news",
          "entertainment",
          "education"
        ],
        "section_title": "Latest Markets News on One News Page",
        "title": "Better Buy: Johnson & Johnson vs. Merck",
        "title_full": "Better Buy: Johnson & Johnson vs. Merck - One News Page",
        "published": "2016-11-16T00:59:45.148+02:00",
        "replies_count": 0,
        "participants_count": 1,
        "site_type": "news",
        "country": "US",
        "spam_score": 0.0,
        "main_image": "http://cdn.newsserve.net/ONPglobe128.png",
        "performance_score": 0,
        "domain_rank": 91686,
        "social": {
          "facebook": {
            "likes": 0,
            "comments": 0,
            "shares": 0
          },
          "gplus": {
            "shares": 0
          },
          "pinterest": {
            "shares": 0
          },
          "linkedin": {
            "shares": 0
          },
          "stumbledupon": {
            "shares": 0
          },
          "vk": {
            "shares": 0
          }
        }
      },
      "uuid": "a5599ab62691f3bd336eb6e4abdeac345336cf42",
      "url": "http://omgili.com/ri/jHIAmI4hxg9BcPFu_4VOJxXOPE7_XaSqp9Z2h_C16MuFpAX6dnivotWIYqINysAU6KpzwR2avPjBlQcvvJGukn7GazLHxCNfYPkRqcwDXXg80bc52MwUuQ--",
      "ord_in_thread": 0,
      "author": "onenewspage.com",
      "published": "2016-11-16T00:59:45.148+02:00",
      "title": "Better Buy: Johnson & Johnson vs. Merck",
      "text": "Johnson & Johnson has Imbruvica. Merck has Keytruda. Which of these 2 giant drugmakers with superstar cancer drugs is the better pick for long-term investors?",
      "highlightText": "",
      "highlightTitle": "",
      "language": "english",
      "external_links": [],
      "entities": {
        "persons": [],
        "organizations": [
          {
            "name": "merck johnson & johnson",
            "sentiment": "positive"
          },
          {
            "name": "johnson & johnson",
            "sentiment": "positive"
          },
          {
            "name": "merck",
            "sentiment": "positive"
          }
        ],
        "locations": []
      },
      "crawled": "2016-11-16T00:59:45.148+02:00"
    },
    {
      "thread": {
        "uuid": "777ed0f1b8ced73940063888ff79e632f2d4d4e1",
        "url": "http://omgili.com/ri/jHIAmI4hxg_lXD5cNG56Yn7FsrOQ2Z2qbAG7YmvLHoJMdMnKaIOXkrbkBhxKdksLeeCotraKmS68CJfb.adF0H51Efc_64zLmnuZoEHVnmbcKOvlTh4p5Q--",
        "site_full": "www.fool.com",
        "site": "fool.com",
        "site_section": "http://www.fool.com/feeds/index.aspx?id=foolwatch&format=rss2\r",
        "site_categories": [
          "news"
        ],
        "section_title": "Motley Fool Headlines",
        "title": "Better Buy: Johnson & Johnson vs. Merck",
        "title_full": "Better Buy: Johnson & Johnson vs. Merck -- The Motley Fool",
        "published": "2016-11-15T02:00:00.000+02:00",
        "replies_count": 0,
        "participants_count": 1,
        "site_type": "news",
        "country": "US",
        "spam_score": 0.0,
        "main_image": "https://g.foolcdn.com/image/?url=http%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F419370%2F3-scientists-in-lab.jpg&h=630&w=1200&op=resize",
        "performance_score": 0,
        "domain_rank": 1336,
        "social": {
          "facebook": {
            "likes": 0,
            "comments": 0,
            "shares": 0
          },
          "gplus": {
            "shares": 0
          },
          "pinterest": {
            "shares": 0
          },
          "linkedin": {
            "shares": 0
          },
          "stumbledupon": {
            "shares": 0
          },
          "vk": {
            "shares": 0
          }
        }
      },
      "uuid": "777ed0f1b8ced73940063888ff79e632f2d4d4e1",
      "url": "http://omgili.com/ri/jHIAmI4hxg_lXD5cNG56Yn7FsrOQ2Z2qbAG7YmvLHoJMdMnKaIOXkrbkBhxKdksLeeCotraKmS68CJfb.adF0H51Efc_64zLmnuZoEHVnmbcKOvlTh4p5Q--",
      "ord_in_thread": 0,
      "author": "foxnews.com",
      "published": "2016-11-15T02:00:00.000+02:00",
      "title": "Better Buy: Johnson & Johnson vs. Merck",
      "text": "Johnson & Johnson has Imbruvica. Merck has Keytruda. Which of these 2 giant drugmakers with superstar cancer drugs is the better pick for long-term investors?",
      "highlightText": "",
      "highlightTitle": "",
      "language": "english",
      "external_links": [],
      "entities": {
        "persons": [],
        "organizations": [
          {
            "name": "merck johnson & johnson",
            "sentiment": "positive"
          },
          {
            "name": "johnson & johnson",
            "sentiment": "positive"
          },
          {
            "name": "merck",
            "sentiment": "positive"
          }
        ],
        "locations": []
      },
      "crawled": "2016-11-16T01:22:18.959+02:00"
    },
    {
      "thread": {
        "uuid": "f87a291470e76e37350aba0b3e8d314cca45dc8a",
        "url": "http://omgili.com/ri/GiCaV2xJNYtgEmkZrq8ydi8hNYw3qv4ZqLHn5gHG0n7J1sE6ZWTeLJVKshYXvsP_ZOOlCEgQJUSxAXgGTywCKgcHfYDXE0CbI.lww1jsj7ZAZMTfl8unwCHFD2nImb5whJvOycTVcBhUT4B8wY7q5OrfEpWS7yliOS6DUjButP9onK8HesJRaAm8trwUJlvTw8X.rkbtfqo-",
        "site_full": "journalstar.com",
        "site": "journalstar.com",
        "site_section": "http://journalstar.com/search/?f=rss&amp;t=article&amp;l=50&amp;s=start_time&amp;sd=desc&amp;k%5B%5D=%23topstory",
        "site_categories": [
          "news"
        ],
        "section_title": "journalstar.com - RSS Results",
        "title": "Better Buy: Johnson & Johnson vs. Merck",
        "title_full": "Better Buy: Johnson & Johnson vs. Merck",
        "published": "2016-11-16T01:56:58.685+02:00",
        "replies_count": 0,
        "participants_count": 0,
        "site_type": "news",
        "country": "US",
        "spam_score": 0.0,
        "main_image": "http://bloximages.chicago2.vip.townnews.com/journalstar.com/content/tncms/assets/v3/editorial/b/de/bded092b-4924-5c89-96e9-e6f4e1c33289/580fd7019fee4.image.jpg?resize=580%2C387",
        "performance_score": 0,
        "domain_rank": 25831,
        "social": {
          "facebook": {
            "likes": 0,
            "comments": 0,
            "shares": 0
          },
          "gplus": {
            "shares": 0
          },
          "pinterest": {
            "shares": 0
          },
          "linkedin": {
            "shares": 0
          },
          "stumbledupon": {
            "shares": 0
          },
          "vk": {
            "shares": 0
          }
        }
      },
      "uuid": "f87a291470e76e37350aba0b3e8d314cca45dc8a",
      "url": "http://omgili.com/ri/GiCaV2xJNYtgEmkZrq8ydi8hNYw3qv4ZqLHn5gHG0n7J1sE6ZWTeLJVKshYXvsP_ZOOlCEgQJUSxAXgGTywCKgcHfYDXE0CbI.lww1jsj7ZAZMTfl8unwCHFD2nImb5whJvOycTVcBhUT4B8wY7q5OrfEpWS7yliOS6DUjButP9onK8HesJRaAm8trwUJlvTw8X.rkbtfqo-",
      "ord_in_thread": 0,
      "author": "",
      "published": "2016-11-16T01:56:58.685+02:00",
      "title": "Better Buy: Johnson & Johnson vs. Merck",
      "text": "Better Buy: Johnson & Johnson vs. Merck \nIf you owned shares of either Johnson & Johnson (NYSE: JNJ) or Merck (NYSE: MRK) over the last five years, you're likely a happy camper. Both stocks are up more than 75% during the period. Both have also seen their shares climb by double-digit percentages this year, with Merck outperforming J&J by around 5%. Which is the better choice for investors looking at 2017 and beyond? Here's how J&J and Merck stack up. Latest Business Achievements",
      "highlightText": "",
      "highlightTitle": "",
      "language": "english",
      "external_links": [],
      "entities": {
        "persons": [
          {
            "name": "merck",
            "sentiment": "none"
          }
        ],
        "organizations": [
          {
            "name": "johnson & johnson",
            "sentiment": "positive"
          },
          {
            "name": "merck better buy: johnson & johnson",
            "sentiment": "neutral"
          },
          {
            "name": "merck  if",
            "sentiment": "neutral"
          },
          {
            "name": "j&j",
            "sentiment": "none"
          },
          {
            "name": "merck",
            "sentiment": "none"
          },
          {
            "name": "nyse",
            "sentiment": "none"
          }
        ],
        "locations": []
      },
      "crawled": "2016-11-16T01:56:58.685+02:00"
    },
    {
      "thread": {
        "uuid": "eec03c25eddd9bf84ae09bb2e2500dd1b79097d5",
        "url": "http://omgili.com/ri/jHIAmI4hxg_lXD5cNG56Yn7FsrOQ2Z2qbAG7YmvLHoJMdMnKaIOXkrbkBhxKdksLeeCotraKmS68CJfb.adF0H51Efc_64zLmnuZoEHVnmbr7S1.uRhaGyYDa6HMi8QWdoZ.cMMtBr_cmQni7Sc1HQ--",
        "site_full": "www.fool.com",
        "site": "fool.com",
        "site_section": "http://feeds-project.fool.com/feeds/foolwatch",
        "site_categories": [
          "news"
        ],
        "section_title": "Motley Fool Headlines",
        "title": "Better Buy: Johnson & Johnson vs. Merck",
        "title_full": "Better Buy: Johnson & Johnson vs. Merck",
        "published": "2016-11-16T03:59:50.316+02:00",
        "replies_count": 0,
        "participants_count": 1,
        "site_type": "blogs",
        "country": "US",
        "spam_score": 0.0,
        "main_image": null,
        "performance_score": 0,
        "domain_rank": 1336,
        "social": {
          "facebook": {
            "likes": 0,
            "comments": 0,
            "shares": 0
          },
          "gplus": {
            "shares": 0
          },
          "pinterest": {
            "shares": 0
          },
          "linkedin": {
            "shares": 0
          },
          "stumbledupon": {
            "shares": 0
          },
          "vk": {
            "shares": 0
          }
        }
      },
      "uuid": "eec03c25eddd9bf84ae09bb2e2500dd1b79097d5",
      "url": "http://omgili.com/ri/jHIAmI4hxg_lXD5cNG56Yn7FsrOQ2Z2qbAG7YmvLHoJMdMnKaIOXkrbkBhxKdksLeeCotraKmS68CJfb.adF0H51Efc_64zLmnuZoEHVnmbr7S1.uRhaGyYDa6HMi8QWdoZ.cMMtBr_cmQni7Sc1HQ--",
      "ord_in_thread": 0,
      "author": "newsfeedback@fool.com (Keith Speights)",
      "published": "2016-11-16T03:59:50.316+02:00",
      "title": "Better Buy: Johnson & Johnson vs. Merck",
      "text": "If you owned shares of either Johnson & Johnson (NYSE: JNJ) or Merck (NYSE: MRK) over the last five years, you're likely a happy camper. Both stocks are up more than 75% during the period. Both have also seen their shares climb by double-digit percentages this year, with Merck outperforming J&J by around 5%. Which is the better choice for investors looking at 2017 and beyond? Here's how J&J and Merck stack up.\n\nImage source: Getty Images.\nContinue reading ",
      "highlightText": "",
      "highlightTitle": "",
      "language": "english",
      "external_links": [],
      "entities": {
        "persons": [
          {
            "name": "merck",
            "sentiment": "none"
          }
        ],
        "organizations": [
          {
            "name": "merck if",
            "sentiment": "positive"
          },
          {
            "name": "johnson & johnson",
            "sentiment": "positive"
          },
          {
            "name": "nyse",
            "sentiment": "positive"
          },
          {
            "name": "merck",
            "sentiment": "positive"
          },
          {
            "name": "j&j",
            "sentiment": "none"
          },
          {
            "name": "getty images",
            "sentiment": "none"
          }
        ],
        "locations": []
      },
      "crawled": "2016-11-16T03:59:50.316+02:00"
    },
    {
      "thread": {
        "uuid": "2d7f26962c033e96347622ec1dd5dbae49209414",
        "url": "http://omgili.com/ri/_0JOtn.4SCpiCBmMVL.n5VSp7bN2UMPTGRXoOri7DxThyI_v5DHdYUmkFig0eJ8E0djr4POuuQUts2WXcyC4D4QO7NAbFqk4ejTtkN6BIFPuAUHbEM5MH888Bxf2K2g55Q8qL1nawQH0jX8ESUA2eSgIZhaqhIkpeYkZjfor0.P1_.RVTvsADgmumabB5Alp7znBlNwk8Oc-",
        "site_full": "billingsgazette.com",
        "site": "billingsgazette.com",
        "site_section": "http://billingsgazette.com/search/?f=rss&amp;t=article&amp;l=50&amp;s=start_time&amp;sd=desc&amp;k[]=%23topstory",
        "site_categories": [
          "news"
        ],
        "section_title": "billingsgazette.com - RSS Results",
        "title": "Better Buy: Johnson & Johnson vs. Merck",
        "title_full": "Better Buy: Johnson & Johnson vs. Merck",
        "published": "2016-11-16T04:54:38.734+02:00",
        "replies_count": 0,
        "participants_count": 0,
        "site_type": "blogs",
        "country": "US",
        "spam_score": 0.0,
        "main_image": "http://bloximages.chicago2.vip.townnews.com/billingsgazette.com/content/tncms/assets/v3/editorial/3/8c/38ce6546-8967-5f93-bb7c-9d3ca755fbd6/580fd9eabf3bd.image.jpg?crop=580%2C326%2C0%2C30&amp;resize=580%2C326&amp;order=crop%2Cresize",
        "performance_score": 0,
        "domain_rank": 43095,
        "social": {
          "facebook": {
            "likes": 0,
            "comments": 0,
            "shares": 0
          },
          "gplus": {
            "shares": 0
          },
          "pinterest": {
            "shares": 0
          },
          "linkedin": {
            "shares": 0
          },
          "stumbledupon": {
            "shares": 0
          },
          "vk": {
            "shares": 0
          }
        }
      },
      "uuid": "2d7f26962c033e96347622ec1dd5dbae49209414",
      "url": "http://omgili.com/ri/_0JOtn.4SCpiCBmMVL.n5VSp7bN2UMPTGRXoOri7DxThyI_v5DHdYUmkFig0eJ8E0djr4POuuQUts2WXcyC4D4QO7NAbFqk4ejTtkN6BIFPuAUHbEM5MH888Bxf2K2g55Q8qL1nawQH0jX8ESUA2eSgIZhaqhIkpeYkZjfor0.P1_.RVTvsADgmumabB5Alp7znBlNwk8Oc-",
      "ord_in_thread": 0,
      "author": "",
      "published": "2016-11-16T04:54:38.734+02:00",
      "title": "Better Buy: Johnson & Johnson vs. Merck",
      "text": "Better Buy: Johnson & Johnson vs. Merck \nIf you owned shares of either Johnson & Johnson (NYSE: JNJ) or Merck (NYSE: MRK) over the last five years, you're likely a happy camper. Both stocks are up more than 75% during the period. Both have also seen their shares climb by double-digit percentages this year, with Merck outperforming J&J by around 5%. Which is the better choice for investors looking at 2017 and beyond? Here's how J&J and Merck stack up. Popular in this section",
      "highlightText": "",
      "highlightTitle": "",
      "language": "english",
      "external_links": [],
      "entities": {
        "persons": [
          {
            "name": "merck",
            "sentiment": "none"
          }
        ],
        "organizations": [
          {
            "name": "johnson & johnson",
            "sentiment": "positive"
          },
          {
            "name": "merck better buy: johnson & johnson",
            "sentiment": "neutral"
          },
          {
            "name": "merck  if",
            "sentiment": "neutral"
          },
          {
            "name": "j&j",
            "sentiment": "none"
          },
          {
            "name": "merck",
            "sentiment": "none"
          },
          {
            "name": "nyse",
            "sentiment": "none"
          }
        ],
        "locations": []
      },
      "crawled": "2016-11-16T04:54:38.734+02:00"
    },
    {
      "thread": {
        "uuid": "ca258dbbf4df10327b4043efe6a88d181ed6a2b7",
        "url": "http://omgili.com/ri/jHIAmI4hxg9BcPFu_4VOJxXOPE7_XaSqp9Z2h_C16MuFpAX6dnivogc1SJbuSB6UOyuUPO3kNymlwljER40CSL5lORwjv0CYxYjFNwNQTdAwc7qMO7L3o1TDcquSMney",
        "site_full": "www.onenewspage.com",
        "site": "onenewspage.com",
        "site_section": "http://www.onenewspage.com/rss/latest/Markets.rss",
        "site_categories": [
          "news",
          "entertainment",
          "education"
        ],
        "section_title": "Latest Markets News on One News Page",
        "title": "Costly Biotech Bet Still Worth It for J&J",
        "title_full": "Costly Biotech Bet Still Worth It for J&J - One News Page",
        "published": "2016-11-28T20:13:22.563+02:00",
        "replies_count": 0,
        "participants_count": 1,
        "site_type": "news",
        "country": "US",
        "spam_score": 0.0,
        "main_image": "http://cdn.newsserve.net/ONPglobe128.png",
        "performance_score": 0,
        "domain_rank": 91686,
        "social": {
          "facebook": {
            "likes": 0,
            "comments": 0,
            "shares": 0
          },
          "gplus": {
            "shares": 0
          },
          "pinterest": {
            "shares": 0
          },
          "linkedin": {
            "shares": 0
          },
          "stumbledupon": {
            "shares": 0
          },
          "vk": {
            "shares": 0
          }
        }
      },
      "uuid": "ca258dbbf4df10327b4043efe6a88d181ed6a2b7",
      "url": "http://omgili.com/ri/jHIAmI4hxg9BcPFu_4VOJxXOPE7_XaSqp9Z2h_C16MuFpAX6dnivogc1SJbuSB6UOyuUPO3kNymlwljER40CSL5lORwjv0CYxYjFNwNQTdAwc7qMO7L3o1TDcquSMney",
      "ord_in_thread": 0,
      "author": "onenewspage.com",
      "published": "2016-11-28T20:13:22.563+02:00",
      "title": "Costly Biotech Bet Still Worth It for J&J",
      "text": "A deal for Actelion Pharmaceuticals would help Johnson & Johnson generate growth.",
      "highlightText": "",
      "highlightTitle": "",
      "language": "english",
      "external_links": [],
      "entities": {
        "persons": [],
        "organizations": [
          {
            "name": "actelion pharmaceuticals",
            "sentiment": "positive"
          },
          {
            "name": "johnson & johnson",
            "sentiment": "positive"
          },
          {
            "name": "j&j",
            "sentiment": "positive"
          }
        ],
        "locations": []
      },
      "crawled": "2016-11-28T20:13:22.563+02:00"
    }
  ],
  "totalResults": 8,
  "moreResultsAvailable": 0,
  "next": "/search?token=c6052904-f312-436b-a6d8-d915084ac866&format=json&ts=1480356802563&q=language%3A%28english%29+thread.country%3AUS+organization.positive%3A%22Johnson+%26+Johnson%22",
  "requestsLeft": 1056
}
